Shots:

• The P-III EMPEROR Trial involves assessing of Jardiance (10 mg) vs PBO in two studies EMPEROR-Reduced [NCT03057977- N=3-730] & EMPEROR-Preserved [NCT03057951- N=5-990] in patients with HFrEF & HFpEF respectively
• The EMPEROR-Reduced study meets its 1EPs in reducing the risk for the composite of cardiovascular death or hospitalization due to heart failure while the overall safety profile was similar. Additionally- the full data of the stay will be presented at ESC 2020 on Aug 29- 2020- with expected regulatory submissions are planned in 2020
• Jardiance is a prescribed drug administered along with diet and exercise to lower blood sugar in and helps in reduction of CV death in adults with T2D

Ref: Eli Lilly | Image: Eli Lilly